Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Uranium Energy Corp (UEC) Price & Performance

CVS Health CorpTrade
Uranium Energy CorpTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Uranium Energy Corp — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Uranium Energy Corp trades at $9.24 (market cap $4.69B). The key difference: CVS Health Corp is far larger — about 24× Uranium Energy Corp's market cap, and CVS Health Corp pays a 3.02% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Uranium Energy Corp for 37 Days on average.

CVSUEC
Market Cap
$112.49B$4.69B
Volume
8,467,3928,957,476
Sector
HealthEnergy
52-Week High
$110.60$20.14
52-Week Low
$70.08$9.04
Typical Hold Time
83 Days37 Days
Enterprise Value
$174.83B$4.20B
Dividend Yield
3.02%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.

CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.

Uranium Energy Corp

Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37M with a net loss of $137M, reflecting operational expansion but negative profitability. Recent news highlights UEC's transition to a multi-mine producer with improved production scale and a $93.13 realized uranium price, though earnings quality concerns persist due to inventory-driven revenue.

UEC presents a high-risk, high-reward opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting weak fundamentals. Key risks include sustained losses, unproven production sustainability, and uranium price volatility. The stock's upside depends on successful execution of U.S. uranium production ramp-up amid growing nuclear demand.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

UEC
57% Buy43% Sell
Avg holding period · 37 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Uranium Energy Corp

Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.

Read more on UEC →